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Nanotechnology is the study, production and controlled manipulation of materials with a 
grain size < 100 nm. At this level, the laws of classical mechanics fall away and those of 
quantum mechanics take over, resulting in unique behaviour of matter in terms of melting 
point, conductivity and reactivity. Additionally, and likely more significant, as grain size 
decreases, the ratio of surface area to volume drastically increases, allowing for greater 
interaction between implants and the surrounding cellular environment. This favourable 
increase in surface area plays an important role in mesenchymal cell differentiation and 
ultimately bone–implant interactions.
Basic science and translational research have revealed important potential applications 
for nanotechnology in orthopaedic surgery, particularly with regard to improving the 
interaction between implants and host bone. Nanophase materials more closely match the 
architecture of native trabecular bone, thereby greatly improving the osseo-integration of 
orthopaedic implants. Nanophase-coated prostheses can also reduce bacterial adhesion 
more than conventionally surfaced prostheses. Nanophase selenium has shown great 
promise when used for tumour reconstructions, as has nanophase silver in the 
management of traumatic wounds. Nanophase silver may significantly improve healing of 
peripheral nerve injuries, and nanophase gold has powerful anti-inflammatory effects on 
tendon inflammation. 
Considerable advances must be made in our understanding of the potential health risks 
of production, implantation and wear patterns of nanophase devices before they are 
approved for clinical use. Their potential, however, is considerable, and is likely to benefit us 
all in the future.
Cite this article: Bone Joint J 2014; 96-B:569–73.
The chemical reactions and molecular interac-
tions that take place in the human body involve
matter composed of 4 to 400 atoms that are
measured in nanometres (nm).1,2 
Nanotechnology is the production and manip-
ulation of materials on a scale of < 100 nm and
the integration of these nanoscopic materials
into microscopic and macroscopic systems.1,3 In
1959, Richard Feynman first introduced the
concept of nanotechnology, describing “a field
in which little has been done, but in which an
enormous amount can be done in principle”.4
Since then, nanotechnology has seen major
advances and real-life applications in the fields
of electronics, water and air filtration, metallic
surface technology, cosmetics, homeware, med-
icine and much more.5 Furthermore, market
research performed by BCC Research predicts
that annual global nanotechnology sales will
reach $48.9 billion by 2017.6 
The classical laws of physics do not apply at
the nano-level, at which nanomaterials exhibit
novel and markedly different properties from
those of materials composed of larger parti-
cles.1,3,7 Nanophase materials are composed of
matter with a grain size much smaller than that
of their conventional counterparts, but with
the same basic atomic structure. There are two
fundamental characteristics that distinguish
one from the other. The first is that the behav-
iour of nanophase materials is explained by
quantum, rather than classical, mechanics.
Particles with a grain size < 100 nm behave in
a markedly different way from larger particles
in terms of melting point, conductivity, com-
bustibility and reactivity.7 The second is the
concept that as grain size decreases, surface
area increases for a given volume. For exam-
ple, a volume of 1 cm3 filled with cubes of
1 μm3 has a total surface area of 6 m2, whereas
the same volume filled with cubes of 1 nm3 has
a total surface area of 6000 m2. On a more
practical level, reducing the grain size of an
orthopaedic implant surface coating from
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micrometres to nanometres increases its surface area by a
factor of thousands.8 This fundamental principle is what
gives nanotechnology the potential to be “the transforma-
tional technology of this century” in the orthopaedic device
industry.9 Basic science and translational research have
revealed important potential applications in orthopaedics.
In this review, we discuss the current and future roles of
nanotechnology as they relate to total joint replacement
(TJR), orthopaedic trauma surgery, oncology, the preven-
tion and treatment of orthopaedic-related infections, soft-
tissue regeneration and orthopaedic drug delivery systems. 
Nanotechnology and bone cell function
When biomaterials are introduced into the human body,
interactions between the surface of the biomaterial and the
surrounding bone and soft tissues are critical to cellular dif-
ferentiation and osseo-integration (bony adherence to the
implant surface). Mesenchymal stromal cells appear to be
one of the first cell types involved when a nanophase bioma-
terial is introduced into a cellular environment.10 By mimick-
ing the nanoscopic, three-dimensional (3D) extracellular and
cell surface topography, nanophase implant surfaces and
scaffolds may improve osseo-integration by promoting both
differentiation of these mesenchymal stromal cells and the
adsorption of the extracellular adhesion molecules essential
to osteoblast function.11,12 Multiple in vitro studies have
shown their ability to control and enhance osteoblast differ-
entiation and cellular adhesion by the introduction of
uniquely shaped nanophase scaffolds without the use of
additional osteogenic chemicals.10,11,13,14 One promising
area of future research is the development of specific osteo-
genic, extracellular nano-topographical surfaces that mimic
known biological configurations. For example, type X colla-
gen is thought to induce endochondral ossification through
its known nano-topographical structure.
Reproducing this may allow the controlled enhancement
of the endochondral ossification of secondary bone heal-
ing.14 A variety of nanostructured materials have been
shown to enhance osteoblast function. These include the
nanophase ceramics, aluminium oxide and titanium dioxide;
carbon; selenium; titanium alloy (Ti6AlV); cobalt–chrome
alloys; and nanocrystalline diamond.15-21 Furthermore, mul-
tiple in vitro studies have shown more osteoid mineralisation
on nano surfaces than on micro-roughened surfaces.22-24
Extracellular adhesion proteins, such as fibronectin and
vitronectin, also play an important role in mediating the
recognition, activation and adhesion of the osteoblast to a
biomaterial, ultimately leading to osseo-integration.25,26
Fibronectin and vitronectin interact more effectively with
nanophase implant surfaces than with conventional sur-
faces.7,15 In addition to the increased quantity of biomole-
cules adsorbed onto the nanosurface, their conformation is
altered by interaction with the nanosurface to increase the
availability of specific cell-adhesive epitopes within each
biomolecule.16,25 The resulting increased adsorption and
favourable conformational changes of fibronectin and
vitronectin, optimise the environment for osteoblast
adhesion.7,15 Overall, these findings suggest that nanoma-
terials have considerable potential use in surfacing ortho-
paedic implants by virtue of their capacity for improved
osseo-integration and osteoid mineralisation.
Orthopaedic applications
Aseptic loosening is the leading cause of TJR failure. It may
be the result of loosening after initial integration of the
implant, or a failure to integrate from the outset.27,28
The application of a nanotextured material may reduce
the risk of implant failure by improving osseo-integra-
tion.7,15,25,26,29 Mature bone has an inorganic mineral size
of roughly 50 nm × 25 nm × 4 nm, which represents a
coarse surface in nanometric terms.8,30 In contrast, mod-
ern orthopaedic implant surfaces are smooth at the nano-
metric level.7 Smooth surfaces preferentially induce the
growth of fibrous tissue rather than bone, whereas a
nanotextured surface may enhance the function of osteo-
blasts and reduce that of fibroblasts. This differential cel-
lular activity is seen on nanotextured hydroxyapatite-
coated surfaces, as well as on many other nanostructured
surfaces, and is thought to be a direct result of their
decreased grain size.7,15,17 In addition to the favourable
properties of nanophase hydroxyapatite, nano-engineered
titanium and cobalt–chromium–molybdenum (CoCrMo)
encourage osteoblast adhesion more than their conven-
tional counterparts.15
Nanocrystalline hydroxyapatite (HA) paste has been
used as a filler of bone defects, with encouraging results. A
series of fractures of the distal radius showed this to be an
acceptable substitute for bone graft in metaphyseal
defects.31 A further series by the same group showed sim-
ilarly encouraging results when it was used to treat meta-
physeal defects in fractures of the tibial plateau.32 
Nanocomposite scaffolds composed of type I collagen
and nanostructured HA are currently being used in the
treatment of osteochondral defects of the knee. Kon et al33
have shown encouraging short-term clinical and radiologi-
cal results with a nanocomposite biological implant for the
treatment of focal osteochondral lesions. They used a tri-
layered biological implant consisting of a cartilage layer
(100% type I collagen), a transition region (Nano-HA 40%
and type I collagen 60%), and a bone region (Nano-HA
70% and type I collagen 30%). This type of implant may be
an easier, less morbid and cell-free ‘off-the-shelf’ solution to
focal defects of articular cartilage than either two-stage
autologous chondrocyte engineering procedures or single-
stage autograft mosaicplasty.33,34 
Recent research in oncology has shown selenium to be a
powerful potentiator of chemotherapeutic agents.35 When
manufactured on the nanometric scale and applied to tita-
nium orthopaedic implants, nanophase selenium appears to
inhibit the growth of malignant osteoblasts at the implant–
tissue interface.36 Similarly, nanophase HA causes in vitro
inhibition and apoptosis of osteosarcoma cells.37 
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Nanophase silver is proving a significant source of inter-
est for orthopaedic traumatologists. Silver has been used on
wounds for centuries as an antibacterial agent. Over the
past decade, nanophase silver dressings have reached the
market and proved to be better at preventing wound infec-
tions and stimulating healing than traditional silver-based
or plain dressings.38,39 Similarly, nanophase silver incorpo-
rated onto the surface of titanium orthopaedic implants in
the form of titanium nanotubes, has immediate powerful
bactericidal and anti-adhesive effects, which last up to
30 days.40 This could eventually prove to be of benefit in
the prevention of the acute post-operative infection of TJRs
and trauma implants.
Peripheral nerve injuries may also benefit from nano-
technology. Ding et al41 have shown that nanophase silver-
impregnated type I collagen scaffolds significantly increase
the quantity of adsorbed proteins critical to nerve healing
and significantly reduce the time to nerve regeneration. In a
study that compared nanosilver-impregnated type I colla-
gen scaffolds to control type I collagen scaffolds in rabbits
with an experimentally induced 10 mm sciatic nerve defect,
the nanosilver-impregnated group showed thicker myelin
sheaths, improved nerve conduction and higher rates of
laminin adsorption.41
A significant amount of energy is currently being directed
at precision delivery of drugs. Gold has the potential to be
an effective transcutaneous drug delivery system for ionto-
phoresis in the treatment of tendinopathy. Dohnert et al42
used a rat Achilles tendinopathy model to show that
diclofenac administered with 30 nm gold nanoparticles by
iontophoresis significantly lowered levels of the inflamma-
tory cytokines interleukin 1 (IL1)-β and tumour necrosis
factor (TNF)-α in tendinopathic tissue compared with both
untreated controls and diclofenac-only groups. This sug-
gests that nanophase gold may enhance the effectiveness of
diclofenac as a transcutaneous anti-inflammatory agent.42
In addition to nanophase gold, nanofibre poly-L-lactic acid
(PLLA) appears to be an excellent nanoscopic drug delivery
system. Large calvarial bony defects close rapidly with
increased expression of osteoblastic lineage cells when
nanofibre PLLA is used as the delivery system for bone
morphogenetic protein (BMP)-2.12 
Nanophase drug delivery systems are also being studied
for their application in TJR. Li et al43 used a biodegradable
polypeptide nanofilm coating on total joint prostheses for
the delivery of cefazolin into a simulated TJR environment
and observed a reduction of bacterial load and improved
osteoblastic response. The adhesion of Staphylococcus
aureus (S. aureus) onto a bare nanofilm implant surface
was substantially less than on a conventional prosthesis.
Furthermore, when the same polypeptide nanofilm was
loaded with cefazolin and used as a drug delivery system, it
produced a dose-related reduction in the S. aureus popula-
tion. This system also has the ability to tightly control the
pharmacokinetics of cefazolin release. Polypeptide nano-
films allow for the targeted release of cefazolin therapy dur-
ing the critical post-implantation period (first two hours).
Additionally, compared with a bare implant surface, nano-
film-coated surfaces showed significantly greater osteoblast
adherence, proliferation and viability, whether loaded with
cefazolin or not, making them potentially an ideal surface
for osseo-integration.43
The safety of nanotechnology and areas of future 
research
The principal unanswered questions in nanotechnology are
related to its clinical safety. At present, the health effects of
nanomaterials are essentially unknown. Nanoparticles may
be released into the body over time as a result of the degra-
dation of implanted nanomaterials. In addition, nanoparti-
cles could potentially be harmful to those manufacturing or
disposing of nanocomposite orthopaedic implants.44 The
metabolism of nanoparticles involves various organ sys-
tems, including the blood, liver and kidneys, and may result
in inflammation and oxidative stress.6,45,46 Some research
suggests that nanoparticulate material is associated with
increased cytotoxicity in the brain and lungs,47,48 whereas
others argue that nanodebris may actually facilitate cell via-
bility in bone and lung tissue.47,49 Since 2008, the United
States government has sponsored $1.4 billion of nanotech-
nology research, only 3% of which is devoted to its safety
and effects on health.3 Owing to the uncertainty about
safety, rigorous studies must be conducted to evaluate the
toxicity of nanophase materials before using them on the
population at large. 
Our understanding of the health effects of nanoscopic wear
debris is also limited. Early research on bearing surfaces
showed that > 90% of polyethylene wear debris is < 1000 nm
in diameter; the particle size generally being approximately
500 nm.28 When various immune cells are exposed to nano-
scopic ultra-high molecular weight polyethylene wear debris
in vitro, several important patterns arise. Macrophages are
unable to phagocytose debris < 200 nm in size. On the other
hand, dendritic cells, which are policing cells critical to the
immune response, are capable of initiating a potent immune
response to polyethylene wear debris as small as 50 nm.
When dendritic cells encounter polyethylene wear on this
scale, they release the inflammatory cytokines IL1-β and IL6.
These cytokines may then activate the osteoclastic cells
responsible for osteolysis.50 
A topic currently at the forefront of joint replacement is
the clinical effect of metal-on-metal (MoM) wear debris.
Nanoscopic metal wear debris, with a mean particle size of
25 nm to 36 nm, is thought to be the driving force behind
the toxicity associated with MoM hip replacement.46,51
Dramatically elevated local and systemic cobalt and chro-
mium ion levels have important local and systemic effects.
At the level of the prosthesis itself, a destructive inflamma-
tory response to nanoscopic metal ion wear debris may
occur, resulting in soft tissue damage and pseudotumour
formation.52,53 The clinical significance of elevated
systemic cobalt and chromium ion levels remains largely
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unknown; however, there is concern about their effects on
peripheral and central nervous tissue, as well as on the car-
diovascular and endocrine systems.52,53 
Although still in its infancy, nanotechnology has gained a
firm foothold in the basic science and preclinical realm of
orthopaedic research. Its vast potential is now being real-
ised as we see the early positive results of applied nanotech-
nology in clinical trials. Extensive basic-science research
suggests that many of the promising theoretical benefits of
the application of nanotechnology lie in orthopaedic sur-
gery. A few of the potential applications with excellent
in vitro data include nano-coated joint replacement
implants, with the potential for improved osseo-integration
and countering infection; rapidly incorporating fillers for
osteochondral defects; anti-tumour selenium-coated endo-
prostheses; and powerful targeted drug delivery systems for
the prevention of infection and the treatment of chronic
overuse injuries. 
No benefits in any form have been received or will be received from a commer-
cial party related directly or indirectly to the subject of this article.
This article was primary edited by A. Ross and first proof edited by G. Scott.
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